Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|February 8, 2023

BP Elements

  • BioPharm International's BP Elements, March 2023
  • Volume 2
  • Issue 3

iotaSciences Launches Single-Cell Picker

iotaSciences isoPick is designed to expand handling solutions for cell biology and gene therapy applications.

iotaSciences, a spin-out from Oxford University specializing in single-cell handling solutions, announced completion of its new single-cell picker instrument on Feb. 6, 2023. The isoPick is designed to provide temperature-controlled handling of single cells during isolation, as well as picking through a workflow guided by touchscreen interfaces.

According to a company press release, the isoPick is intended for cell and gene therapy researchers, as well as the wider single-cell research community, as a means of providing verifiable isolation of single cells with high cell viability and stable single-cell outgrowth. Like the company's other instruments, it is designed to have a small footprint instrument that requires minimal maintenance.

Source: iotaSciences

Articles in this issue

over 3 years ago

Evolutions in Vaccine Development

over 3 years ago

Advances in In Vivo CAR T-cell Therapies

over 3 years ago

FDA Issues Guidance on Potency for mAbs and Therapeutic Proteins

over 3 years ago

Bio-Rad’s New StarBright Blue and Yellow Dyes Enhance Multiplex Flow Cytometry

over 3 years ago

Eurofins Viracor Launches Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients

over 3 years ago

Moderna and Life Edit Therapeutics Enter Gene Editing Collaboration

over 3 years ago

AbbVie and Capsida Strike $674 Million Gene Therapy Development Deal

over 3 years ago

Predictive Oncology and Cvergenx Enter Genomics-Based Personalized Therapy Collaboration

over 3 years ago

Charles River Launches Novel IgY-based ELISA Kit

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more